Related Experiment Video

Updated: Apr 12, 2026

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1
11:02

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Published on: May 27, 2016

8.6K

β-arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression

Xuanxuan Jing1, Hui Zhang2, Jing Hu1

  • 1Department of Pathology, Shandong University School of Medicine 44 Wenhua Xi Road, Jinan 250012, Shandong, P. R. China.

International Journal of Clinical and Experimental Pathology
|May 15, 2015
PubMed

Insights

Beta-arrestin 2 plays a key role in multidrug resistance (MDR) in breast cancer by regulating MDR1/p-gp expression. Targeting beta-arrestin 2 may offer new strategies for overcoming MDR in breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Multidrug resistance (MDR) significantly hinders effective breast cancer treatment.
  • Overexpression of MDR1/p-glycoprotein (p-gp) is a primary driver of MDR development.
  • Beta-arrestin 2 is implicated in various aspects of tumor progression.

Purpose of the Study:

  • To investigate the role of beta-arrestin 2 in regulating multidrug resistance in breast cancer.
  • To determine the correlation between beta-arrestin 2 and MDR1/p-gp expression in human breast tissues.

Main Methods:

  • Immunohistochemistry was used to analyze beta-arrestin 2 and MDR1/p-gp protein levels in 106 breast tissue samples.
  • Quantitative real-time reverse polymerase chain reaction (qRT-PCR) and western blotting assessed MDR1/p-gp mRNA and protein expression.
  • Cellular assays (MTS) evaluated drug sensitivity following beta-arrestin 2 manipulation.

Main Results:

  • A significant positive correlation was observed between beta-arrestin 2 and MDR1/p-gp protein expression (P = 0.016).
  • Silencing beta-arrestin 2 reduced MDR1/p-gp expression, while its overexpression increased it in breast cancer cell lines.
  • Modulating beta-arrestin 2 levels affected breast cancer cell sensitivity to chemotherapeutic agents.

Conclusions:

  • Beta-arrestin 2 is a critical regulator of MDR1/p-gp expression in breast cancer.
  • The findings suggest beta-arrestin 2 as a potential therapeutic target for overcoming multidrug resistance.
  • Understanding the beta-arrestin 2 pathway could lead to improved breast cancer treatment strategies.
Keywords:
MDR1/p-gpbreast cancerchemotherapymutidrug resistance (MDR)β-arrestin 2

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.7K
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.5K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
5.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K